A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis
Phase of Trial: Phase II/III
Latest Information Update: 21 Jan 2016
Price : $35 *
At a glance
- Drugs Eprodisate (Primary)
- Indications Amyloid A amyloidosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors BELLUS Health
- 21 Jan 2016 According to Auven Therapeutics media release, company is planning to announce top-line results during the second quarter of 2016.
- 21 Jan 2016 Results published in Auven Therapeutics media release.
- 20 Jan 2014 New trial record